» Articles » PMID: 25431091

Treatment of Bloodstream Infections in ICUs

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2014 Nov 29
PMID 25431091
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Bloodstream infections (BSIs) are frequent in ICU and is a prognostic factor of severe sepsis. Community acquired BSIs usually due to susceptible bacteria should be clearly differentiated from healthcare associated BSIs frequently due to resistant hospital strains. Early adequate treatment is key and should use guidelines and direct examination of samples performed from the infectious source. Previous antibiotic therapy knowledge, history of multi-drug resistant organism (MDRO) carriage are other major determinants of first choice antimicrobials in heathcare-associated and nosocomial BSIs. Initial antimicrobial dose should be adapted to pharmacokinetic knowledge. In general, a high dose is recommended at the beginning of treatment. If MDRO is suspected combination antibiotic therapy is mandatory because it increase the spectrum of treatment. Most of time, combination should be pursued no more than 2 to 5 days.Given the negative impact of useless antimicrobials, maximal effort should be done to decrease the antibiotic selection pressure. De-escalation from a broad spectrum to a narrow spectrum antimicrobial decreases the antibiotic selection pressure without negative impact on mortality. Duration of therapy should be shortened as often as possible especially when organism is susceptible, when the infection source has been totally controlled.

Citing Articles

The Outcome of Hospital-Acquired Bloodstream Infection and Its Associated Factors in Critical Care Unit.

Mohamed Shukri N, Hassan S, Md Noor S, Ab Hamid S, Nik Mohamad N, Wan Muhd Shukeri W Malays J Med Sci. 2025; 31(6):160-177.

PMID: 39830098 PMC: 11740822. DOI: 10.21315/mjms2024.31.6.13.


Investigating the time to blood culture positivity: why does it take so long?.

Falconer K, Hammond R, Parcell B, Gillespie S J Med Microbiol. 2025; 74(1).

PMID: 39757997 PMC: 11701752. DOI: 10.1099/jmm.0.001942.


Evaluation of a new protocol for rapid identification of in blood cultures using the modified bile solubility test: Gram staining is still standing.

Aupaix A, Verroken A, Rodriguez-Villalobos H J Clin Microbiol. 2024; 63(1):e0122224.

PMID: 39692479 PMC: 11784088. DOI: 10.1128/jcm.01222-24.


Clonal background and routes of plasmid transmission underlie antimicrobial resistance features of bloodstream Klebsiella pneumoniae.

Ikhimiukor O, Zac Soligno N, Akintayo I, Marcovici M, Souza S, Workman A Nat Commun. 2024; 15(1):6969.

PMID: 39138200 PMC: 11322185. DOI: 10.1038/s41467-024-51374-x.


Bloodstream infections in the era of the COVID-19 pandemic: Changing epidemiology of antimicrobial resistance in the intensive care unit.

Ntziora F, Giannitsioti E J Intensive Med. 2024; 4(3):269-280.

PMID: 39035613 PMC: 11258508. DOI: 10.1016/j.jointm.2023.12.004.


References
1.
Zahar J, Timsit J, Garrouste-Orgeas M, Francais A, Vesin A, Vesim A . Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011; 39(8):1886-95. DOI: 10.1097/CCM.0b013e31821b827c. View

2.
Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens I, Harbarth S . Society's failure to protect a precious resource: antibiotics. Lancet. 2011; 378(9788):369-71. DOI: 10.1016/S0140-6736(11)60401-7. View

3.
Prowle J, Echeverri J, Ligabo E, Sherry N, Taori G, Crozier T . Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care. 2011; 15(2):R100. PMC: 3219371. DOI: 10.1186/cc10114. View

4.
Seyler L, Cotton F, Taccone F, De Backer D, Macours P, Vincent J . Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011; 15(3):R137. PMC: 3219006. DOI: 10.1186/cc10257. View

5.
Schuetz P, Chiappa V, Briel M, Greenwald J . Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011; 171(15):1322-31. DOI: 10.1001/archinternmed.2011.318. View